Jennifer Doudna startup Azalea Therapeutics launches with $82Mnews2025-11-04T13:00:49+00:00November 4th, 2025|Endpoints News|
UniQure’s Huntington’s gene therapy is delayed, as FDA suggests it may walk back accelerated approval blessingnews2025-11-03T13:34:28+00:00November 3rd, 2025|Endpoints News|
Caribou says it’s cracked ‘off-the-shelf’ cell therapy, but needs to raise money to move forwardnews2025-11-03T12:00:16+00:00November 3rd, 2025|Endpoints News|
Baby KJ researchers publish FDA interactions as agency eyes new pathwaynews2025-10-31T19:14:34+00:00October 31st, 2025|Endpoints News|
Post-Hoc Live: Meet the scientists behind Baby KJ’s life-saving CRISPR therapynews2025-10-31T11:00:14+00:00October 31st, 2025|Endpoints News|
Gilead sees cell therapy sales decline in Q3news2025-10-31T01:45:15+00:00October 31st, 2025|Endpoints News|
Kyverna says small group of rare disease patients all responded to its CAR-Tnews2025-10-29T14:44:27+00:00October 29th, 2025|Endpoints News|
BioMarin looks to divest hemophilia gene therapy Roctaviannews2025-10-28T15:29:37+00:00October 28th, 2025|Endpoints News|
Intellia pauses two CRISPR trials after liver toxicity hospitalizes patientnews2025-10-27T16:48:44+00:00October 27th, 2025|Endpoints News|
Intellia pauses two CRISPR trials after liver toxicity hospitalizes patientnews2025-10-27T16:48:44+00:00October 27th, 2025|Endpoints News|
